{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T01:51:08Z","timestamp":1774576268674,"version":"3.50.1"},"reference-count":225,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41584-026-01352-y","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T10:36:33Z","timestamp":1772015793000},"page":"239-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic masqueraders of paediatric and adult rheumatic diseases"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4369-7082","authenticated-orcid":false,"given":"Steven H.","family":"Lang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8813-9335","authenticated-orcid":false,"given":"Cher","family":"Sha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6101-5633","authenticated-orcid":false,"given":"Chelsi M.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6450-8554","authenticated-orcid":false,"given":"V. Reid","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0857-133X","authenticated-orcid":false,"given":"Tiphanie P.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5108-8861","authenticated-orcid":false,"given":"Lindsay C.","family":"Burrage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"1352_CR1","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10545-015-9893-x","volume":"38","author":"E Morava","year":"2015","unstructured":"Morava, E. et al. Quo vadis: the re-definition of \u201cinborn metabolic diseases\u201d. J. Inherit. Metab. Dis. 38, 1003\u20131006 (2015).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR2","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.08.021102","volume":"8","author":"D Waters","year":"2018","unstructured":"Waters, D. et al. Global birth prevalence and mortality from inborn errors of metabolism: a systematic analysis of the evidence. J. Glob. Health 8, 021102 (2018).","journal-title":"J. Glob. Health"},{"key":"1352_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5606\/ArchRheumatol.2018.6262","volume":"33","author":"CS Kasapkara","year":"2018","unstructured":"Kasapkara, C. S., Akcaboy, M., Kara Eroglu, F. & Derinkuyu, B. E. Mucolipidosis type III: a rare disease in differential diagnosis of joint stiffness in pediatric rheumatology. Arch. Rheumatol. 33, 93\u201398 (2018).","journal-title":"Arch. Rheumatol."},{"key":"1352_CR4","first-page":"133","volume":"20","author":"R Brik","year":"1993","unstructured":"Brik, R. et al. Mucolipidosis III presenting as a rheumatological disorder. J. Rheumatol. 20, 133\u2013136 (1993).","journal-title":"J. Rheumatol."},{"key":"1352_CR5","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.nmd.2017.04.013","volume":"27","author":"RS Scalco","year":"2017","unstructured":"Scalco, R. S. et al. Misdiagnosis is an important factor for diagnostic delay in McArdle disease. Neuromuscul. Disord. 27, 852\u2013855 (2017).","journal-title":"Neuromuscul. Disord."},{"key":"1352_CR6","first-page":"89","volume":"49","author":"FB Lagler","year":"2019","unstructured":"Lagler, F. B. et al. Extent, impact, and predictors of diagnostic delay in Pompe disease: a combined survey approach to unveil the diagnostic odyssey. JIMD Rep. 49, 89\u201395 (2019).","journal-title":"JIMD Rep."},{"key":"1352_CR7","doi-asserted-by":"publisher","first-page":"15924","DOI":"10.3390\/ijms242115924","volume":"24","author":"D Marotto","year":"2023","unstructured":"Marotto, D. et al. Late-onset Pompe disease with normal creatine kinase levels: the importance of rheumatological suspicion. Int. J. Mol. Sci. 24, 15924 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1352_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5152\/eurjrheum.2022.21156","volume":"10","author":"T Yuce Inel","year":"2023","unstructured":"Yuce Inel, T., Koken Avsar, A., Teke Kisa, P., Ozer, E. & Sari, I. A challenging etiology of myopathy: the late-onset Pompe disease. Eur. J. Rheumatol. 10, 26\u201328 (2023).","journal-title":"Eur. J. Rheumatol."},{"key":"1352_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s13023-023-02810-6","volume":"18","author":"A Loret","year":"2023","unstructured":"Loret, A. et al. Joint manifestations revealing inborn metabolic diseases in adults: a narrative review. Orphanet J. Rare Dis. 18, 239 (2023).","journal-title":"Orphanet J. Rare Dis."},{"key":"1352_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1546-0096-7-18","volume":"7","author":"R Cimaz","year":"2009","unstructured":"Cimaz, R. et al. Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis. Pediatr. Rheumatol. Online J. 7, 18 (2009).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1352_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10067-010-1445-z","volume":"30","author":"R Cimaz","year":"2011","unstructured":"Cimaz, R. et al. Awareness of Fabry disease among rheumatologists \u2014 current status and perspectives. Clin. Rheumatol. 30, 467\u2013475 (2011).","journal-title":"Clin. Rheumatol."},{"key":"1352_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.pcl.2018.12.007","volume":"66","author":"NAV Fabie","year":"2019","unstructured":"Fabie, N. A. V., Pappas, K. B. & Feldman, G. L. The current state of newborn screening in the United States. Pediatr. Clin. North. Am. 66, 369\u2013386 (2019).","journal-title":"Pediatr. Clin. North. Am."},{"key":"1352_CR13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/jimd.12348","volume":"44","author":"CR Ferreira","year":"2021","unstructured":"Ferreira, C. R., Rahman, S., Keller, M., Zschocke, J. & Group, I. A. An international classification of inherited metabolic disorders (ICIMD). J. Inherit. Metab. Dis. 44, 164\u2013177 (2021).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41584-025-01250-9","volume":"21","author":"A Gul","year":"2025","unstructured":"Gul, A. et al. The pathogenesis, clinical presentations and treatment of monogenic systemic vasculitis. Nat. Rev. Rheumatol. 21, 414\u2013425 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1352_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/annurev-immunol-081619-104850","volume":"38","author":"DG Ryan","year":"2020","unstructured":"Ryan, D. G. & O\u2019Neill, L. A. J. Krebs cycle reborn in macrophage immunometabolism. Annu. Rev. Immunol. 38, 289\u2013313 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"1352_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/978-1-0716-2565-1_29","volume":"2546","author":"D Scott","year":"2022","unstructured":"Scott, D., Clinton Frazee, C. 3rd & Garg, U. Screening of organic acidurias by gas chromatography-mass spectrometry (GC-MS). Methods Mol. Biol. 2546, 321\u2013333 (2022).","journal-title":"Methods Mol. Biol."},{"key":"1352_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ymgme.2018.07.011","volume":"125","author":"LR Ranganath","year":"2018","unstructured":"Ranganath, L. R. et al. Nitisinone arrests ochronosis and decreases rate of progression of alkaptonuria: evaluation of the effect of nitisinone in the United Kingdom national alkaptonuria centre. Mol. Genet. Metab. 125, 127\u2013134 (2018).","journal-title":"Mol. Genet. Metab."},{"key":"1352_CR18","doi-asserted-by":"publisher","first-page":"33110","DOI":"10.1074\/jbc.271.51.33110","volume":"271","author":"J Koch","year":"1996","unstructured":"Koch, J. et al. Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification Of the first molecular lesion causing Farber disease. J. Biol. Chem. 271, 33110\u201333115 (1996).","journal-title":"J. Biol. Chem."},{"key":"1352_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/BF01600282","volume":"420","author":"L Zappatini-Tommasi","year":"1992","unstructured":"Zappatini-Tommasi, L., Dumontel, C., Guibaud, P. & Girod, C. Farber disease: an ultrastructural study. Report of a case and review of the literature. Virchows Arch. A Pathol. Anat. Histopathol. 420, 281\u2013290 (1992).","journal-title":"Virchows Arch. A Pathol. Anat. Histopathol."},{"key":"1352_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bbadis.2016.11.031","volume":"1863","author":"S Dworski","year":"2017","unstructured":"Dworski, S. et al. Acid ceramidase deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy. Biochim. Biophys. Acta Mol. Basis Dis. 1863, 386\u2013394 (2017).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"1352_CR21","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1038\/s41598-018-20052-6","volume":"8","author":"FPS Yu","year":"2018","unstructured":"Yu, F. P. S., Dworski, S. & Medin, J. A. Deletion of MCP-1 impedes pathogenesis of acid ceramidase deficiency. Sci. Rep. 8, 1808 (2018).","journal-title":"Sci. Rep."},{"key":"1352_CR22","doi-asserted-by":"publisher","first-page":"E1213","DOI":"10.1152\/ajpendo.00480.2012","volume":"304","author":"L Arana","year":"2013","unstructured":"Arana, L. et al. Ceramide 1-phosphate induces macrophage chemoattractant protein-1 release: involvement in ceramide 1-phosphate-stimulated cell migration. Am. J. Physiol. Endocrinol. Metab. 304, E1213\u2013E1226 (2013).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1352_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/gim.2017.133","volume":"20","author":"M Zielonka","year":"2018","unstructured":"Zielonka, M., Garbade, S. F., Kolker, S., Hoffmann, G. F. & Ries, M. A cross-sectional quantitative analysis of the natural history of Farber disease: an ultra-orphan condition with rheumatologic and neurological cardinal disease features. Genet. Med. 20, 524\u2013530 (2018).","journal-title":"Genet. Med."},{"key":"1352_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13023-018-0845-z","volume":"13","author":"FPS Yu","year":"2018","unstructured":"Yu, F. P. S., Amintas, S., Levade, T. & Medin, J. A. Acid ceramidase deficiency: Farber disease and SMA-PME. Orphanet J. Rare Dis. 13, 121 (2018).","journal-title":"Orphanet J. Rare Dis."},{"key":"1352_CR25","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s10545-012-9573-z","volume":"36","author":"MM Kostik","year":"2013","unstructured":"Kostik, M. M. et al. Farber lipogranulomatosis with predominant joint involvement mimicking juvenile idiopathic arthritis. J. Inherit. Metab. Dis. 36, 1079\u20131080 (2013).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR26","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1002\/art.39659","volume":"68","author":"L Bonafe","year":"2016","unstructured":"Bonafe, L. et al. Brief report: peripheral osteolysis in adults linked to ASAH1 (Acid Ceramidase) mutations: a new presentation of Farber\u2019s disease. Arthritis Rheumatol. 68, 2323\u20132327 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"1352_CR27","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1016\/j.ymgme.2016.11.325","volume":"120","author":"A Solyom","year":"2016","unstructured":"Solyom, A. et al. Farber disease (acid ceramidase deficiency) epidemiology: literature review and patient cohort data indicate moderate and attenuated phenotypes are likely underrepresented in the medical literature and are underdiagnosed. Mol. Genet. Metab. 120, S124\u2013S125 (2016).","journal-title":"Mol. Genet. Metab."},{"key":"1352_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/jimd.12043","volume":"42","author":"K Ehlert","year":"2019","unstructured":"Ehlert, K. et al. Allogeneic hematopoietic cell transplantation in Farber disease. J. Inherit. Metab. Dis. 42, 286\u2013294 (2019).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR29","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1016\/j.ymgme.2015.12.364","volume":"117","author":"J Mitchell","year":"2016","unstructured":"Mitchell, J. et al. Farber disease: implications of anti-inflammatory treatment. Mol. Genet. Metab. 117, S82 (2016).","journal-title":"Mol. Genet. Metab."},{"key":"1352_CR30","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1172\/JCI111025","volume":"72","author":"OT Mueller","year":"1983","unstructured":"Mueller, O. T., Honey, N. K., Little, L. E., Miller, A. L. & Shows, T. B. Mucolipidosis II and III. The genetic relationships between two disorders of lysosomal enzyme biosynthesis. J. Clin. Invest. 72, 1016\u20131023 (1983).","journal-title":"J. Clin. Invest."},{"key":"1352_CR31","doi-asserted-by":"publisher","first-page":"6812","DOI":"10.3390\/ijms21186812","volume":"21","author":"SA Khan","year":"2020","unstructured":"Khan, S. A. & Tomatsu, S. C. Mucolipidoses overview: past, present, and future. Int. J. Mol. Sci. 21, 6812\u00a0(2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1352_CR32","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1038\/s41436-021-01244-4","volume":"23","author":"EJ Dogterom","year":"2021","unstructured":"Dogterom, E. J. et al. Mucolipidosis type II and type III: a systematic review of 843 published cases. Genet. Med. 23, 2047\u20132056 (2021).","journal-title":"Genet. Med."},{"key":"1352_CR33","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/014107689909200508","volume":"92","author":"C Hetherington","year":"1999","unstructured":"Hetherington, C., Harris, N. J. & Smith, T. W. Orthopaedic management in four cases of mucolipidosis type III. J. R. Soc. Med. 92, 244\u2013246 (1999).","journal-title":"J. R. Soc. Med."},{"key":"1352_CR34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/jmg.2009.067736","volume":"47","author":"SS Cathey","year":"2010","unstructured":"Cathey, S. S. et al. Phenotype and genotype in mucolipidoses II and III alpha\/beta: a study of 61 probands. J. Med. Genet. 47, 38\u201348 (2010).","journal-title":"J. Med. Genet."},{"key":"1352_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1440-1754.2010.01715.x","volume":"46","author":"G David-Vizcarra","year":"2010","unstructured":"David-Vizcarra, G. et al. The natural history and osteodystrophy of mucolipidosis types II and III. J. Paediatr. Child. Health 46, 316\u2013322 (2010).","journal-title":"J. Paediatr. Child. Health"},{"key":"1352_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1148\/106.1.153","volume":"106","author":"R Melhem","year":"1973","unstructured":"Melhem, R., Dorst, J. P., Scott, C. I. Jr. & McKusick, V. A. Roentgen findings in mucolipidosis III (Pseudo-Hurler polydystrophy). Radiology 106, 153\u2013160 (1973).","journal-title":"Radiology"},{"key":"1352_CR37","unstructured":"Raas-Rothschild, A. & Spiegel, R. Mucolipidosis III gamma. In GeneReviews (eds Adam, M. P. et al.) (2019)."},{"key":"1352_CR38","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.gene.2017.11.052","volume":"642","author":"B Tuysuz","year":"2018","unstructured":"Tuysuz, B. et al. Mucolipidosis type III gamma: three novel mutation and genotype-phenotype study in eleven patients. Gene 642, 398\u2013407 (2018).","journal-title":"Gene"},{"key":"1352_CR39","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1023\/A:1022935115323","volume":"25","author":"C Robinson","year":"2002","unstructured":"Robinson, C. et al. The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment. J. Inherit. Metab. Dis. 25, 681\u2013693 (2002).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR40","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3390\/biom11070951","volume":"11","author":"V Gragnaniello","year":"2021","unstructured":"Gragnaniello, V. et al. Newborn screening for Fabry disease in northeastern Italy: results of five years of experience. Biomolecules 11, 951\u00a0(2021).","journal-title":"Biomolecules"},{"key":"1352_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","volume":"190","author":"BK Burton","year":"2017","unstructured":"Burton, B. K. et al. Newborn screening for lysosomal storage disorders in Illinois: the initial 15-month experience. J. Pediatr. 190, 130\u2013135 (2017).","journal-title":"J. Pediatr."},{"key":"1352_CR42","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1001\/jamapediatrics.2018.0263","volume":"172","author":"PV Hopkins","year":"2018","unstructured":"Hopkins, P. V. et al. Incidence of 4 lysosomal storage disorders from 4 years of newborn screening. JAMA Pediatr. 172, 696\u2013697 (2018).","journal-title":"JAMA Pediatr."},{"key":"1352_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1420067","volume":"11","author":"H Kurdi","year":"2024","unstructured":"Kurdi, H., Lavalle, L., Moon, J. C. C. & Hughes, D. Inflammation in Fabry disease: stages, molecular pathways, and therapeutic implications. Front. Cardiovasc. Med. 11, 1420067 (2024).","journal-title":"Front. Cardiovasc. Med."},{"key":"1352_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","volume":"122","author":"P Rozenfeld","year":"2017","unstructured":"Rozenfeld, P. & Feriozzi, S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol. Genet. Metab. 122, 19\u201327 (2017).","journal-title":"Mol. Genet. Metab."},{"key":"1352_CR45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","volume":"109","author":"PN De Francesco","year":"2013","unstructured":"De Francesco, P. N., Mucci, J. M., Ceci, R., Fossati, C. A. & Rozenfeld, P. A. Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. Mol. Genet. Metab. 109, 93\u201399 (2013).","journal-title":"Mol. Genet. Metab."},{"key":"1352_CR46","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","volume":"47","author":"T DeGraba","year":"2000","unstructured":"DeGraba, T. et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann. Neurol. 47, 229\u2013233 (2000).","journal-title":"Ann. Neurol."},{"key":"1352_CR47","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin, R. J. et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry registry. Pediatr. Res. 64, 550\u2013555 (2008).","journal-title":"Pediatr. Res."},{"key":"1352_CR48","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejim.2016.03.015","volume":"32","author":"E Verrecchia","year":"2016","unstructured":"Verrecchia, E. et al. The impact of fever\/hyperthermia in the diagnosis of Fabry: a retrospective analysis. Eur. J. Intern. Med. 32, 26\u201330 (2016).","journal-title":"Eur. J. Intern. Med."},{"key":"1352_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1454","volume":"8","author":"Y Luo","year":"2020","unstructured":"Luo, Y., Wu, D. & Shen, M. Recurrent fever of unknown origin: an overlooked symptom of Fabry disease. Mol. Genet. Genomic Med. 8, e1454 (2020).","journal-title":"Mol. Genet. Genomic Med."},{"key":"1352_CR50","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng, C. M. et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry. J. Inherit. Metab. Dis. 30, 184\u2013192 (2007).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR51","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10545-010-9261-9","volume":"34","author":"A Gal","year":"2011","unstructured":"Gal, A., Hughes, D. A. & Winchester, B. Toward a consensus in the laboratory diagnostics of Fabry disease \u2014 recommendations of a European expert group. J. Inherit. Metab. Dis. 34, 509\u2013514 (2011).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR52","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/cge.13546","volume":"96","author":"DP Germain","year":"2019","unstructured":"Germain, D. P. et al. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin. Genet. 96, 107\u2013117 (2019).","journal-title":"Clin. Genet."},{"key":"1352_CR53","volume":"7","author":"R El Dib","year":"2016","unstructured":"El Dib, R. et al. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst. Rev. 7, CD006663 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1352_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173358","volume":"12","author":"R El Dib","year":"2017","unstructured":"El Dib, R. et al. Enzyme replacement therapy for Anderson-Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS ONE 12, e0173358 (2017).","journal-title":"PLoS ONE"},{"key":"1352_CR55","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain, D. P. et al. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N. Engl. J. Med. 375, 545\u2013555 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1352_CR56","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0006-291X(65)90743-6","volume":"18","author":"RO Brady","year":"1965","unstructured":"Brady, R. O., Kanfer, J. N. & Shapiro, D. Metabolism of glucocerebrosides. ii. evidence of an enzymatic deficiency in Gaucher\u2019s Disease. Biochem. Biophys. Res. Commun. 18, 221\u2013225 (1965).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1352_CR57","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/jbmr.3734","volume":"34","author":"D Hughes","year":"2019","unstructured":"Hughes, D. et al. Gaucher disease in bone: from pathophysiology to practice. J. Bone Min. Res. 34, 996\u20131013 (2019).","journal-title":"J. Bone Min. Res."},{"key":"1352_CR58","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.bbadis.2007.04.002","volume":"1772","author":"MJ van Breemen","year":"2007","unstructured":"van Breemen, M. J. et al. Increased plasma macrophage inflammatory protein (MIP)-1\u03b1 and MIP-1\u03b2 levels in type 1 Gaucher disease. Biochim. Biophys. Acta 1772, 788\u2013796 (2007).","journal-title":"Biochim. Biophys. Acta"},{"key":"1352_CR59","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1182\/blood-2009-02-205708","volume":"114","author":"PM Campeau","year":"2009","unstructured":"Campeau, P. M. et al. Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood 114, 3181\u20133190 (2009).","journal-title":"Blood"},{"key":"1352_CR60","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1309\/BG5VA8JRDQH1M7HN","volume":"122","author":"LA Boven","year":"2004","unstructured":"Boven, L. A. et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am. J. Clin. Pathol. 122, 359\u2013369 (2004).","journal-title":"Am. J. Clin. Pathol."},{"key":"1352_CR61","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1172\/JCI117084","volume":"93","author":"CE Hollak","year":"1994","unstructured":"Hollak, C. E., van Weely, S., van Oers, M. H. & Aerts, J. M. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J. Clin. Invest. 93, 1288\u20131292 (1994).","journal-title":"J. Clin. Invest."},{"key":"1352_CR62","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature21368","volume":"543","author":"MK Pandey","year":"2017","unstructured":"Pandey, M. K. et al. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature 543, 108\u2013112 (2017).","journal-title":"Nature"},{"key":"1352_CR63","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.smim.2018.02.006","volume":"37","author":"MK Pandey","year":"2018","unstructured":"Pandey, M. K., Grabowski, G. A. & Kohl, J. An unexpected player in Gaucher disease: the multiple roles of complement in disease development. Semin. Immunol. 37, 30\u201342 (2018).","journal-title":"Semin. Immunol."},{"key":"1352_CR64","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/jcm12010085","volume":"12","author":"G Castillon","year":"2022","unstructured":"Castillon, G., Chang, S. C. & Moride, Y. Global incidence and prevalence of Gaucher disease: a targeted literature review. J. Clin. Med. 12, 85\u00a0(2022).","journal-title":"J. Clin. Med."},{"key":"1352_CR65","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ajmg.a.32253","volume":"149A","author":"MA Faden","year":"2009","unstructured":"Faden, M. A., Krakow, D., Ezgu, F., Rimoin, D. L. & Lachman, R. S. The Erlenmeyer flask bone deformity in the skeletal dysplasias. Am. J. Med. Genet. A 149A, 1334\u20131345 (2009).","journal-title":"Am. J. Med. Genet. A"},{"key":"1352_CR66","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/art.1780250616","volume":"25","author":"Z Weizman","year":"1982","unstructured":"Weizman, Z., Tennenbaum, A. & Yatziv, S. Interphalangeal joint involvement in Gaucher\u2019s disease, type I, resembling juvenile rheumatoid arthritis. Arthritis Rheum. 25, 706\u2013707 (1982).","journal-title":"Arthritis Rheum."},{"key":"1352_CR67","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","volume":"36","author":"NJ Weinreb","year":"2013","unstructured":"Weinreb, N. J. et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J. Inherit. Metab. Dis. 36, 543\u2013553 (2013).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR68","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s13023-022-02573-6","volume":"17","author":"A Dardis","year":"2022","unstructured":"Dardis, A. et al. Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1. Orphanet J. Rare Dis. 17, 442 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"1352_CR69","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ymgme.2021.12.009","volume":"135","author":"PS Kishnani","year":"2022","unstructured":"Kishnani, P. S. et al. Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: results from a Delphi consensus. Mol. Genet. Metab. 135, 154\u2013162 (2022).","journal-title":"Mol. Genet. Metab."},{"key":"1352_CR70","doi-asserted-by":"publisher","first-page":"9912","DOI":"10.3390\/ijms22189912","volume":"22","author":"JC Serfecz","year":"2021","unstructured":"Serfecz, J. C. et al. C5a Activates a pro-inflammatory gene expression profile in human Gaucher iPSC-derived macrophages. Int. J. Mol. Sci. 22, 9912\u00a0(2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1352_CR71","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/gim.2014.25","volume":"16","author":"M Beck","year":"2014","unstructured":"Beck, M. et al. The natural history of MPS I: global perspectives from the MPS I Registry. Genet. Med. 16, 759\u2013765 (2014).","journal-title":"Genet. Med."},{"key":"1352_CR72","first-page":"196","volume":"24","author":"R Cimaz","year":"2006","unstructured":"Cimaz, R. et al. Attenuated type I mucopolysaccharidosis in the differential diagnosis of juvenile idiopathic arthritis: a series of 13 patients with Scheie syndrome. Clin. Exp. Rheumatol. 24, 196\u2013202 (2006).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1352_CR73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10545-007-0529-7","volume":"30","author":"AM Montano","year":"2007","unstructured":"Montano, A. M., Tomatsu, S., Gottesman, G. S., Smith, M. & Orii, T. International Morquio A registry: clinical manifestation and natural course of Morquio A disease. J. Inherit. Metab. Dis. 30, 165\u2013174 (2007).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR74","first-page":"59","volume":"9","author":"R Aslam","year":"2013","unstructured":"Aslam, R., van Bommel, A. C. M., Hendriksz, C. J. & Jester, A. Subjective and objective assessment of hand function in mucopolysaccharidosis IVa patients. JIMD Rep. 9, 59\u201365 (2013).","journal-title":"JIMD Rep."},{"key":"1352_CR75","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12920-024-01910-x","volume":"17","author":"M Yi","year":"2024","unstructured":"Yi, M., Shen, P. & Zhang, H. Delayed diagnosis of mild mucopolysaccharidosis type IVA. BMC Med. Genomics 17, 151 (2024).","journal-title":"BMC Med. Genomics"},{"key":"1352_CR76","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0749-0712(01)00010-5","volume":"18","author":"PM Lamberti","year":"2002","unstructured":"Lamberti, P. M. & Light, T. R. Carpal tunnel syndrome in children. Hand Clin. 18, 331\u2013337 (2002).","journal-title":"Hand Clin."},{"key":"1352_CR77","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1136\/archdischild-2020-319040","volume":"106","author":"R Giugliani","year":"2021","unstructured":"Giugliani, R., Muschol, N., Keenan, H. A., Dant, M. & Muenzer, J. Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I. Arch. Dis. Child. 106, 674\u2013679 (2021).","journal-title":"Arch. Dis. Child."},{"key":"1352_CR78","first-page":"67","volume":"8","author":"S Bruni","year":"2016","unstructured":"Bruni, S., Lavery, C. & Broomfield, A. The diagnostic journey of patients with mucopolysaccharidosis I: a real-world survey of patient and physician experiences. Mol. Genet. Metab. Rep. 8, 67\u201373 (2016).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"1352_CR79","first-page":"116","volume":"65","author":"D Mathis","year":"2024","unstructured":"Mathis, D. et al. Specific GAG ratios in the diagnosis of mucopolysaccharidoses. JIMD Rep. 65, 116\u2013123 (2024).","journal-title":"JIMD Rep."},{"key":"1352_CR80","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.gim.2021.12.013","volume":"24","author":"ET Strovel","year":"2022","unstructured":"Strovel, E. T. et al. Measurement of lysosomal enzyme activities: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 24, 769\u2013783 (2022).","journal-title":"Genet. Med."},{"key":"1352_CR81","doi-asserted-by":"crossref","unstructured":"Spranger, J. R. W. et al. Bone Dysplasias: An Atlas of Genetic Disorders of Skeletal Development 3rd edn (Oxford University Press, 2012).","DOI":"10.1093\/med\/9780195396089.001.0001"},{"key":"1352_CR82","volume":"6","author":"E Jameson","year":"2019","unstructured":"Jameson, E., Jones, S. & Remmington, T. Enzyme replacement therapy with laronidase (Aldurazyme\u00ae) for treating mucopolysaccharidosis type I. Cochrane Database Syst. Rev. 6, CD009354 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1352_CR83","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ymgme.2020.07.005","volume":"131","author":"PE Wikman-Jorgensen","year":"2020","unstructured":"Wikman-Jorgensen, P. E. et al. Enzyme replacement therapy for the treatment of Hunter disease: a systematic review with narrative synthesis and meta-analysis. Mol. Genet. Metab. 131, 206\u2013210 (2020).","journal-title":"Mol. Genet. Metab."},{"key":"1352_CR84","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ymgme.2016.05.006","volume":"118","author":"SA Jones","year":"2016","unstructured":"Jones, S. A. et al. A phase 1\/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. Mol. Genet. Metab. 118, 198\u2013205 (2016).","journal-title":"Mol. Genet. Metab."},{"key":"1352_CR85","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","volume":"37","author":"CJ Hendriksz","year":"2014","unstructured":"Hendriksz, C. J. et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J. Inherit. Metab. Dis. 37, 979\u2013990 (2014).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR86","doi-asserted-by":"publisher","first-page":"e681","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"P Harmatz","year":"2005","unstructured":"Harmatz, P. et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115, e681\u2013e689 (2005).","journal-title":"Pediatrics"},{"key":"1352_CR87","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ymgme.2013.04.023","volume":"109","author":"S Laraway","year":"2013","unstructured":"Laraway, S., Breen, C., Mercer, J., Jones, S. & Wraith, J. E. Does early use of enzyme replacement therapy alter the natural history of mucopolysaccharidosis I? Experience in three siblings. Mol. Genet. Metab. 109, 315\u2013316 (2013).","journal-title":"Mol. Genet. Metab."},{"key":"1352_CR88","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s10038-019-0662-9","volume":"64","author":"HH Chen","year":"2019","unstructured":"Chen, H. H. et al. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future. J. Hum. Genet. 64, 1153\u20131171 (2019).","journal-title":"J. Hum. Genet."},{"key":"1352_CR89","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/art.38877","volume":"67","author":"SM Wakil","year":"2015","unstructured":"Wakil, S. M. et al. Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 67, 288\u2013295 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"1352_CR90","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12969-016-0124-2","volume":"14","author":"T Kallinich","year":"2016","unstructured":"Kallinich, T. et al. Juvenile arthritis caused by a novel FAMIN (LACC1) mutation in two children with systemic and extended oligoarticular course. Pediatr. Rheumatol. Online J. 14, 63 (2016).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1352_CR91","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201006","volume":"218","author":"O Omarjee","year":"2021","unstructured":"Omarjee, O. et al. LACC1 deficiency links juvenile arthritis with autophagy and metabolism in macrophages. J. Exp. Med. 218, e20201006\u00a0(2021).","journal-title":"J. Exp. Med."},{"key":"1352_CR92","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1038\/s41467-025-57744-3","volume":"16","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Crohn\u2019s Disease-associated variant in laccase domain containing 1 (LACC1) modulates T cell gene expression, metabolism and T cell function. Nat. Commun. 16, 2577 (2025).","journal-title":"Nat. Commun."},{"key":"1352_CR93","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-022-05111-3","volume":"609","author":"Z Wei","year":"2022","unstructured":"Wei, Z., Oh, J., Flavell, R. A. & Crawford, J. M. LACC1 bridges NOS2 and polyamine metabolism in inflammatory macrophages. Nature 609, 348\u2013353 (2022).","journal-title":"Nature"},{"key":"1352_CR94","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.2175","volume":"11","author":"Y Wu","year":"2023","unstructured":"Wu, Y., Wang, S., Yin, W., Yin, W. & Ding, Y. Clinical characteristics and genotype analysis of a Chinese patient with juvenile arthritis due to novel LACC1 frameshift mutation and literature review. Mol. Genet. Genomic Med. 11, e2175 (2023).","journal-title":"Mol. Genet. Genomic Med."},{"key":"1352_CR95","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng0996-19","volume":"14","author":"JM Fernandez-Canon","year":"1996","unstructured":"Fernandez-Canon, J. M. et al. The molecular basis of alkaptonuria. Nat. Genet. 14, 19\u201324 (1996).","journal-title":"Nat. Genet."},{"key":"1352_CR96","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/BF03401625","volume":"2","author":"AE Garrod","year":"1996","unstructured":"Garrod, A. E. The incidence of alkaptonuria: a study in chemical individuality. 1902. Mol. Med. 2, 274\u2013282 (1996).","journal-title":"Mol. Med."},{"key":"1352_CR97","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1093\/rheumatology\/keq175","volume":"49","author":"D Braconi","year":"2010","unstructured":"Braconi, D. et al. Evaluation of anti-oxidant treatments in an in vitro model of alkaptonuric ochronosis. Rheumatology 49, 1975\u20131983 (2010).","journal-title":"Rheumatology"},{"key":"1352_CR98","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10545-015-9842-8","volume":"38","author":"L Millucci","year":"2015","unstructured":"Millucci, L. et al. Amyloidosis in alkaptonuria. J. Inherit. Metab. Dis. 38, 797\u2013805 (2015).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR99","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.joca.2018.05.017","volume":"26","author":"D Braconi","year":"2018","unstructured":"Braconi, D. et al. Inflammatory and oxidative stress biomarkers in alkaptonuria: data from the DevelopAKUre project. Osteoarthritis Cartilage 26, 1078\u20131086 (2018).","journal-title":"Osteoarthritis Cartilage"},{"key":"1352_CR100","unstructured":"Harris, H. Garrod's Inborn Errors of Metabolism (Oxford University Press,1963)."},{"key":"1352_CR101","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1126\/science.126.3266.209","volume":"126","author":"RA Milch","year":"1957","unstructured":"Milch, R. A., Titus, E. D. & Loo, T. L. Atmospheric oxidation of homogentisic acid: spectrophotometric studies. Science 126, 209\u2013210 (1957).","journal-title":"Science"},{"key":"1352_CR102","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/S0049-0172(03)00080-5","volume":"33","author":"A Mannoni","year":"2004","unstructured":"Mannoni, A. et al. Alkaptonuria, ochronosis, and ochronotic arthropathy. Semin. Arthritis Rheum. 33, 239\u2013248 (2004).","journal-title":"Semin. Arthritis Rheum."},{"key":"1352_CR103","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s10545-011-9374-9","volume":"34","author":"LR Ranganath","year":"2011","unstructured":"Ranganath, L. R. & Cox, T. F. Natural history of alkaptonuria revisited: analyses based on scoring systems. J. Inherit. Metab. Dis. 34, 1141\u20131151 (2011).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR104","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1056\/NEJMoa021736","volume":"347","author":"C Phornphutkul","year":"2002","unstructured":"Phornphutkul, C. et al. Natural history of alkaptonuria. N. Engl. J. Med. 347, 2111\u20132121 (2002).","journal-title":"N. Engl. J. Med."},{"key":"1352_CR105","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/jimd.12647","volume":"46","author":"MJ Kujawa","year":"2023","unstructured":"Kujawa, M. J. et al. Clinical presentation of 13 children with alkaptonuria. J. Inherit. Metab. Dis. 46, 916\u2013930 (2023).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR106","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1515\/jpem-2019-0163","volume":"33","author":"AI Akbaba","year":"2020","unstructured":"Akbaba, A. I., Ozgul, R. K. & Dursun, A. Presentation of 14 alkaptonuria patients from Turkey. J. Pediatr. Endocrinol. Metab. 33, 289\u2013294 (2020).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"1352_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2025.109099","volume":"145","author":"FD Mayrink","year":"2025","unstructured":"Mayrink, F. D., Dorneles, G., da Silva, I. M. & Areda, C. A. Efficacy and safety of nitisinone for patients with alkaptonuria: a systematic review with metanalysis. Mol. Genet. Metab. 145, 109099 (2025).","journal-title":"Mol. Genet. Metab."},{"key":"1352_CR108","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1258\/000456303321016268","volume":"40","author":"E Morava","year":"2003","unstructured":"Morava, E., Kosztolanyi, G., Engelke, U. F. & Wevers, R. A. Reversal of clinical symptoms and radiographic abnormalities with protein restriction and ascorbic acid in alkaptonuria. Ann. Clin. Biochem. 40, 108\u2013111 (2003).","journal-title":"Ann. Clin. Biochem."},{"key":"1352_CR109","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin, M., Jacobsson, L. & Roddy, E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat. Rev. Rheumatol. 16, 380\u2013390 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1352_CR110","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ajhg.2010.02.024","volume":"86","author":"AP de Brouwer","year":"2010","unstructured":"de Brouwer, A. P. et al. PRPS1 mutations: four distinct syndromes and potential treatment. Am. J. Hum. Genet. 86, 506\u2013518 (2010).","journal-title":"Am. J. Hum. Genet."},{"key":"1352_CR111","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/A:1005348504512","volume":"20","author":"WL Nyhan","year":"1997","unstructured":"Nyhan, W. L. The recognition of Lesch-Nyhan syndrome as an inborn error of purine metabolism. J. Inherit. Metab. Dis. 20, 171\u2013178 (1997).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10409238.2020.1832438","volume":"56","author":"V Pareek","year":"2021","unstructured":"Pareek, V., Pedley, A. M. & Benkovic, S. J. Human de novo purine biosynthesis. Crit. Rev. Biochem. Mol. Biol. 56, 1\u201316 (2021).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"1352_CR113","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/0002-9343(64)90104-4","volume":"36","author":"M Lesch","year":"1964","unstructured":"Lesch, M. & Nyhan, W. L. A familial disorder of uric acid metabolism and central nervous system function. Am. J. Med. 36, 561\u2013570 (1964).","journal-title":"Am. J. Med."},{"key":"1352_CR114","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/brain\/awq013","volume":"133","author":"HA Jinnah","year":"2010","unstructured":"Jinnah, H. A. et al. Attenuated variants of Lesch-Nyhan disease. Brain 133, 671\u2013689 (2010).","journal-title":"Brain"},{"key":"1352_CR115","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ymgme.2014.05.012","volume":"112","author":"R Fu","year":"2014","unstructured":"Fu, R., Chen, C. J. & Jinnah, H. A. Genotypic and phenotypic spectrum in attenuated variants of Lesch-Nyhan disease. Mol. Genet. Metab. 112, 280\u2013285 (2014).","journal-title":"Mol. Genet. Metab."},{"key":"1352_CR116","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ymgme.2019.06.001","volume":"127","author":"A Madeo","year":"2019","unstructured":"Madeo, A. et al. Clinical, biochemical and genetic characteristics of a cohort of 101 French and Italian patients with HPRT deficiency. Mol. Genet. Metab. 127, 147\u2013157 (2019).","journal-title":"Mol. Genet. Metab."},{"key":"1352_CR117","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/rheumatology\/key041","volume":"57","author":"M Zikanova","year":"2018","unstructured":"Zikanova, M. et al. Clinical manifestations and molecular aspects of phosphoribosylpyrophosphate synthetase superactivity in females. Rheumatology 57, 1180\u20131185 (2018).","journal-title":"Rheumatology"},{"key":"1352_CR118","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymgme.2022.02.007","volume":"136","author":"A Jurecka","year":"2022","unstructured":"Jurecka, A. & Tylki-Szymanska, A. Inborn errors of purine and pyrimidine metabolism: a guide to diagnosis. Mol. Genet. Metab. 136, 164\u2013176 (2022).","journal-title":"Mol. Genet. Metab."},{"key":"1352_CR119","unstructured":"de Brouwer, A. P. M. & Christodoulou, J. Phosphoribosylpyrophosphate synthetase superactivity. In GeneReviews (eds Adam, M. P. et al.) (2022)."},{"key":"1352_CR120","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1053\/j.ajkd.2025.03.023","volume":"86","author":"MA Baum","year":"2025","unstructured":"Baum, M. A., Mandel, M. & Somers, M. J. G. Understanding rare kidney stone diseases: a review. Am. J. Kidney Dis. 86, 236\u2013244 (2025).","journal-title":"Am. J. Kidney Dis."},{"key":"1352_CR121","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13075-021-02706-5","volume":"24","author":"N Xu","year":"2022","unstructured":"Xu, N. et al. Clinical features of gout in adult patients with type Ia glycogen storage disease: a single-centre retrospective study and a review of literature. Arthritis Res. Ther. 24, 58 (2022).","journal-title":"Arthritis Res. Ther."},{"key":"1352_CR122","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.metabol.2007.04.013","volume":"56","author":"RJ Torres","year":"2007","unstructured":"Torres, R. J., Prior, C. & Puig, J. G. Efficacy and safety of allopurinol in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency. Metabolism 56, 1179\u20131186 (2007).","journal-title":"Metabolism"},{"key":"1352_CR123","unstructured":"Jinnah, H. A. HPRT1 disorders. In GeneReviews (eds Adam, M. P. et al.) (2020)."},{"key":"1352_CR124","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","volume":"71","author":"N Schlesinger","year":"2012","unstructured":"Schlesinger, N. et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann. Rheum. Dis. 71, 1839\u20131848 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1352_CR125","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0889-857X(02)00022-4","volume":"28","author":"RL Wortmann","year":"2002","unstructured":"Wortmann, R. L. & DiMauro, S. Differentiating idiopathic inflammatory myopathies from metabolic myopathies. Rheum. Dis. Clin. North. Am. 28, 759\u2013778 (2002).","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"1352_CR126","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.rdc.2011.01.004","volume":"37","author":"EC Smith","year":"2011","unstructured":"Smith, E. C., El-Gharbawy, A. & Koeberl, D. D. Metabolic myopathies: clinical features and diagnostic approach. Rheum. Dis. Clin. North. Am. 37, 201\u2013217 (2011).","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"1352_CR127","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fphys.2011.00112","volume":"2","author":"J Jensen","year":"2011","unstructured":"Jensen, J., Rustad, P. I., Kolnes, A. J. & Lai, Y. C. The role of skeletal muscle glycogen breakdown for regulation of insulin sensitivity by exercise. Front. Physiol. 2, 112 (2011).","journal-title":"Front. Physiol."},{"key":"1352_CR128","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1186\/s12864-017-4188-2","volume":"18","author":"A Santalla","year":"2017","unstructured":"Santalla, A. et al. Genotypic and phenotypic features of all Spanish patients with McArdle disease: a 2016 update. BMC Genomics 18, 819 (2017).","journal-title":"BMC Genomics"},{"key":"1352_CR129","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.nmd.2021.10.006","volume":"31","author":"A Lucia","year":"2021","unstructured":"Lucia, A. et al. Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group. Neuromuscul. Disord. 31, 1296\u20131310 (2021).","journal-title":"Neuromuscul. Disord."},{"key":"1352_CR130","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1001\/archneur.59.9.1395","volume":"59","author":"RG Haller","year":"2002","unstructured":"Haller, R. G. & Vissing, J. Spontaneous \u201csecond wind\u201d and glucose-induced second \u201csecond wind\u201d in McArdle disease: oxidative mechanisms. Arch. Neurol. 59, 1395\u20131402 (2002).","journal-title":"Arch. Neurol."},{"key":"1352_CR131","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s13023-020-01562-x","volume":"15","author":"RS Scalco","year":"2020","unstructured":"Scalco, R. S. et al. Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC). Orphanet J. Rare Dis. 15, 330 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"1352_CR132","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10545-014-9771-y","volume":"38","author":"N Preisler","year":"2015","unstructured":"Preisler, N., Haller, R. G. & Vissing, J. Exercise in muscle glycogen storage diseases. J. Inherit. Metab. Dis. 38, 551\u2013563 (2015).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR133","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/bjsports-2012-091130","volume":"47","author":"A Lucia","year":"2013","unstructured":"Lucia, A., Quinlivan, R., Wakelin, A., Martin, M. A. & Andreu, A. L. The \u2018McArdle paradox\u2019: exercise is a good advice for the exercise intolerant. Br. J. Sports Med. 47, 728\u2013729 (2013).","journal-title":"Br. J. Sports Med."},{"key":"1352_CR134","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1249\/MSS.0000000000000812","volume":"48","author":"G Nogales-Gadea","year":"2016","unstructured":"Nogales-Gadea, G. et al. Exercise and preexercise nutrition as treatment for McArdle disease. Med. Sci. Sports Exerc. 48, 673\u2013679 (2016).","journal-title":"Med. Sci. Sports Exerc."},{"key":"1352_CR135","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.3390\/biom10091339","volume":"10","author":"NK Meena","year":"2020","unstructured":"Meena, N. K. & Raben, N. Pompe disease: new developments in an old lysosomal storage disorder. Biomolecules 10, 1339 (2020).","journal-title":"Biomolecules"},{"key":"1352_CR136","first-page":"45","volume":"26","author":"N Raben","year":"2007","unstructured":"Raben, N., Roberts, A. & Plotz, P. H. Role of autophagy in the pathogenesis of Pompe disease. Acta Myol. 26, 45\u201348 (2007).","journal-title":"Acta Myol."},{"key":"1352_CR137","doi-asserted-by":"crossref","unstructured":"Kishnani, P. S. et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J. Pediatr. 148, 671\u2013676.","DOI":"10.1016\/j.jpeds.2005.11.033"},{"key":"1352_CR138","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1212\/WNL.52.4.851","volume":"52","author":"MG Ausems","year":"1999","unstructured":"Ausems, M. G. et al. A diagnostic protocol for adult-onset glycogen storage disease type II. Neurology 52, 851\u2013853 (1999).","journal-title":"Neurology"},{"key":"1352_CR139","doi-asserted-by":"publisher","first-page":"e966","DOI":"10.1212\/WNL.0000000000207547","volume":"101","author":"C Lefeuvre","year":"2023","unstructured":"Lefeuvre, C. et al. Characteristics of patients with late-onset Pompe disease in France: insights from the French Pompe Registry in 2022. Neurology 101, e966\u2013e977 (2023).","journal-title":"Neurology"},{"key":"1352_CR140","first-page":"39","volume":"65","author":"D Yue","year":"2024","unstructured":"Yue, D. et al. Diagnostic delay in late-onset Pompe disease among Chinese patients: a retrospective study. JIMD Rep. 65, 39\u201346 (2024).","journal-title":"JIMD Rep."},{"key":"1352_CR141","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ncl.2014.04.010","volume":"32","author":"M Dasouki","year":"2014","unstructured":"Dasouki, M. et al. Pompe disease: literature review and case series. Neurol. Clin. 32, 751\u2013776 (2014). ix.","journal-title":"Neurol. Clin."},{"key":"1352_CR142","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/ajmg.c.31322","volume":"160C","author":"A Schuller","year":"2012","unstructured":"Schuller, A., Wenninger, S., Strigl-Pill, N. & Schoser, B. Toward deconstructing the phenotype of late-onset Pompe disease. Am. J. Med. Genet. C. Semin. Med. Genet. 160C, 80\u201388 (2012).","journal-title":"Am. J. Med. Genet. C. Semin. Med. Genet."},{"key":"1352_CR143","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13023-016-0442-y","volume":"11","author":"CI van Capelle","year":"2016","unstructured":"van Capelle, C. I. et al. Childhood Pompe disease: clinical spectrum and genotype in 31 patients. Orphanet J. Rare Dis. 11, 65 (2016).","journal-title":"Orphanet J. Rare Dis."},{"key":"1352_CR144","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cccn.2004.04.009","volume":"347","author":"NA Chamoles","year":"2004","unstructured":"Chamoles, N. A., Niizawa, G., Blanco, M., Gaggioli, D. & Casentini, C. Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. Clin. Chim. Acta 347, 97\u2013102 (2004).","journal-title":"Clin. Chim. Acta"},{"key":"1352_CR145","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1373\/clinchem.2008.107722","volume":"54","author":"A Dajnoki","year":"2008","unstructured":"Dajnoki, A. et al. Newborn screening for Pompe disease by measuring acid \u03b1-glucosidase activity using tandem mass spectrometry. Clin. Chem. 54, 1624\u20131629 (2008).","journal-title":"Clin. Chem."},{"key":"1352_CR146","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/ijns6010011","volume":"6","author":"TL Klug","year":"2020","unstructured":"Klug, T. L., Swartz, L. B., Washburn, J., Brannen, C. & Kiesling, J. L. Lessons learned from Pompe disease newborn screening and follow-up. Int. J. Neonatal Screen. 6, 11 (2020).","journal-title":"Int. J. Neonatal Screen."},{"key":"1352_CR147","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg, A. T. et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N. Engl. J. Med. 362, 1396\u20131406 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1352_CR148","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/mus.22329","volume":"45","author":"EJ Cupler","year":"2012","unstructured":"Cupler, E. J. et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 45, 319\u2013333 (2012).","journal-title":"Muscle Nerve"},{"key":"1352_CR149","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","volume":"20","author":"J Diaz-Manera","year":"2021","unstructured":"Diaz-Manera, J. et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 20, 1012\u20131026 (2021).","journal-title":"Lancet Neurol."},{"key":"1352_CR150","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/35022595","volume":"406","author":"Y Tanaka","year":"2000","unstructured":"Tanaka, Y. et al. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 406, 902\u2013906 (2000).","journal-title":"Nature"},{"key":"1352_CR151","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00401-015-1385-4","volume":"129","author":"Y Endo","year":"2015","unstructured":"Endo, Y., Furuta, A. & Nishino, I. Danon disease: a phenotypic expression of LAMP-2 deficiency. Acta Neuropathol. 129, 391\u2013398 (2015).","journal-title":"Acta Neuropathol."},{"key":"1352_CR152","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ijcard.2019.01.020","volume":"286","author":"M Brambatti","year":"2019","unstructured":"Brambatti, M. et al. Danon disease: gender differences in presentation and outcomes. Int. J. Cardiol. 286, 92\u201398 (2019).","journal-title":"Int. J. Cardiol."},{"key":"1352_CR153","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.jacc.2023.08.014","volume":"82","author":"KN Hong","year":"2023","unstructured":"Hong, K. N. et al. International consensus on differential diagnosis and management of patients with Danon disease: JACC state-of-the-art review. J. Am. Coll. Cardiol. 82, 1628\u20131647 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1352_CR154","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1056\/NEJMoa2412392","volume":"392","author":"B Greenberg","year":"2024","unstructured":"Greenberg, B. et al. Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease. N. Engl. J. Med. 392, 972\u2013983\u00a0(2024).","journal-title":"N. Engl. J. Med."},{"key":"1352_CR155","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/6815","volume":"21","author":"G Borsani","year":"1999","unstructured":"Borsani, G. et al. SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance. Nat. Genet. 21, 297\u2013301 (1999).","journal-title":"Nat. Genet."},{"key":"1352_CR156","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10545-005-5954-x","volume":"28","author":"L Mannucci","year":"2005","unstructured":"Mannucci, L. et al. Increased NO production in lysinuric protein intolerance. J. Inherit. Metab. Dis. 28, 123\u2013129 (2005).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR157","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3389\/fimmu.2018.00508","volume":"9","author":"BM Rotoli","year":"2018","unstructured":"Rotoli, B. M. et al. Downregulation of SLC7A7 triggers an inflammatory phenotype in human macrophages and airway epithelial cells. Front. Immunol. 9, 508 (2018).","journal-title":"Front. Immunol."},{"key":"1352_CR158","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1038\/s42255-025-01354-2","volume":"7","author":"S Benhmammouch","year":"2025","unstructured":"Benhmammouch, S. et al. Slc7a7 licenses macrophage glutaminolysis for restorative functions in atherosclerosis. Nat. Metab. 7, 1924\u20131938 (2025).","journal-title":"Nat. Metab."},{"key":"1352_CR159","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.673957","volume":"9","author":"JL Contreras","year":"2021","unstructured":"Contreras, J. L. et al. Immune dysregulation mimicking systemic lupus erythematosus in a patient with lysinuric protein intolerance: case report and review of the literature. Front. Pediatr. 9, 673957 (2021).","journal-title":"Front. Pediatr."},{"key":"1352_CR160","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymgme.2012.02.010","volume":"106","author":"H Ogier de Baulny","year":"2012","unstructured":"Ogier de Baulny, H., Schiff, M. & Dionisi-Vici, C. Lysinuric protein intolerance (LPI): a multi organ disease by far more complex than a classic urea cycle disorder. Mol. Genet. Metab. 106, 12\u201317 (2012).","journal-title":"Mol. Genet. Metab."},{"key":"1352_CR161","doi-asserted-by":"publisher","first-page":"C191","DOI":"10.1152\/ajpcell.00583.2006","volume":"293","author":"MP Sperandeo","year":"2007","unstructured":"Sperandeo, M. P. et al. Slc7a7 disruption causes fetal growth retardation by downregulating Igf1 in the mouse model of lysinuric protein intolerance. Am. J. Physiol. Cell Physiol 293, C191\u2013C198 (2007).","journal-title":"Am. J. Physiol. Cell Physiol"},{"key":"1352_CR162","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.metabol.2006.09.011","volume":"56","author":"LM Tanner","year":"2007","unstructured":"Tanner, L. M., Nanto-Salonen, K., Niinikoski, H., Huoponen, K. & Simell, O. Long-term oral lysine supplementation in lysinuric protein intolerance. Metabolism 56, 185\u2013189 (2007).","journal-title":"Metabolism"},{"key":"1352_CR163","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S0026-0495(03)00089-1","volume":"52","author":"M Lukkarinen","year":"2003","unstructured":"Lukkarinen, M., Nanto-Salonen, K., Pulkki, K., Aalto, M. & Simell, O. Oral supplementation corrects plasma lysine concentrations in lysinuric protein intolerance. Metabolism 52, 935\u2013938 (2003).","journal-title":"Metabolism"},{"key":"1352_CR164","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.jaci.2023.03.006","volume":"151","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y. et al. Reversal of SLE and hemophagocytic lymphohistiocytosis caused by lysinuric protein intolerance through allogeneic hematopoietic stem cell transplantation. J. Allergy Clin. Immunol. 151, 1673\u20131674 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1352_CR165","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/ni.3487","volume":"17","author":"MK Akula","year":"2016","unstructured":"Akula, M. K. et al. Control of the innate immune response by the mevalonate pathway. Nat. Immunol. 17, 922\u2013929 (2016).","journal-title":"Nat. Immunol."},{"key":"1352_CR166","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1093\/hmg\/11.25.3115","volume":"11","author":"SM Houten","year":"2002","unstructured":"Houten, S. M. et al. Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum. Mol. Genet. 11, 3115\u20133124 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"1352_CR167","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12969-016-0091-7","volume":"14","author":"S Zhang","year":"2016","unstructured":"Zhang, S. Natural history of mevalonate kinase deficiency: a literature review. Pediatr. Rheumatol. Online J. 14, 30 (2016).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1352_CR168","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jbspin.2014.12.011","volume":"82","author":"S Berody","year":"2015","unstructured":"Berody, S., Galeotti, C., Kone-Paut, I. & Piram, M. A retrospective survey of patients\u2019s journey before the diagnosis of mevalonate kinase deficiency. Jt Bone Spine 82, 240\u2013244 (2015).","journal-title":"Jt Bone Spine"},{"key":"1352_CR169","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11926-010-0086-1","volume":"12","author":"JC van der Hilst","year":"2010","unstructured":"van der Hilst, J. C. & Frenkel, J. Hyperimmunoglobulin D syndrome in childhood. Curr. Rheumatol. Rep. 12, 101\u2013107 (2010).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1352_CR170","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1093\/rheumatology\/kem200","volume":"46","author":"W Ammouri","year":"2007","unstructured":"Ammouri, W. et al. Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology 46, 1597\u20131600 (2007).","journal-title":"Rheumatology"},{"key":"1352_CR171","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/art.42139","volume":"74","author":"M Romano","year":"2022","unstructured":"Romano, M. et al. The 2021 EULAR\/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Arthritis Rheumatol. 74, 1102\u20131121 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1352_CR172","first-page":"33","volume":"27","author":"J Jeyaratnam","year":"2016","unstructured":"Jeyaratnam, J. et al. Diagnostic value of urinary mevalonic acid excretion in patients with a clinical suspicion of mevalonate kinase deficiency (MKD). JIMD Rep. 27, 33\u201338 (2016).","journal-title":"JIMD Rep."},{"key":"1352_CR173","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jaci.2023.06.013","volume":"152","author":"J Berner","year":"2023","unstructured":"Berner, J. et al. Phosphomevalonate kinase deficiency expands the genetic spectrum of systemic autoinflammatory diseases. J. Allergy Clin. Immunol. 152, 1025\u20131031.e2 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1352_CR174","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/cge.14451","volume":"105","author":"A Jairaman","year":"2024","unstructured":"Jairaman, A. et al. A novel homozygous variant in PMVK is associated with enhanced IL1\u03b2 secretion and a hyper-IgD syndrome-like phenotype. Clin. Genet. 105, 302\u2013307 (2024).","journal-title":"Clin. Genet."},{"key":"1352_CR175","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","volume":"378","author":"F De Benedetti","year":"2018","unstructured":"De Benedetti, F. et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N. Engl. J. Med. 378, 1908\u20131919 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1352_CR176","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1136\/ard.2011.149922","volume":"70","author":"EJ Bodar","year":"2011","unstructured":"Bodar, E. J. et al. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann. Rheum. Dis. 70, 2155\u20132158 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"1352_CR177","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/hmg\/8.8.1365","volume":"8","author":"S Stinchi","year":"1999","unstructured":"Stinchi, S. et al. Targeted disruption of the lysosomal \u03b1-mannosidase gene results in mice resembling a mild form of human \u03b1-mannosidosis. Hum. Mol. Genet. 8, 1365\u20131372 (1999).","journal-title":"Hum. Mol. Genet."},{"key":"1352_CR178","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1432-1033.1990.tb15498.x","volume":"189","author":"JC Michalski","year":"1990","unstructured":"Michalski, J. C., Haeuw, J. F., Wieruszeski, J. M., Montreuil, J. & Strecker, G. In vitro hydrolysis of oligomannosyl oligosaccharides by the lysosomal \u03b1-D-mannosidases. Eur. J. Biochem. 189, 369\u2013379 (1990).","journal-title":"Eur. J. Biochem."},{"key":"1352_CR179","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1750-1172-3-21","volume":"3","author":"D Malm","year":"2008","unstructured":"Malm, D. & Nilssen, O. Alpha-mannosidosis. Orphanet J. Rare Dis. 3, 21 (2008).","journal-title":"Orphanet J. Rare Dis."},{"key":"1352_CR180","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10545-013-9622-2","volume":"37","author":"D Malm","year":"2014","unstructured":"Malm, D., Riise Stensland, H. M., Edvardsen, O. & Nilssen, O. The natural course and complications of alpha-mannosidosis \u2014 a retrospective and descriptive study. J. Inherit. Metab. Dis. 37, 79\u201382 (2014).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1352_CR181","volume":"66","author":"AK Saad","year":"2025","unstructured":"Saad, A. K. et al. Retrospective study of clinical and genetic profiles of alpha-mannosidosis patients from the UAE. JIMD Rep. 66, e70001 (2025).","journal-title":"JIMD Rep."},{"key":"1352_CR182","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s00431-004-1404-2","volume":"163","author":"M Urushihara","year":"2004","unstructured":"Urushihara, M. et al. Sisters with \u03b1-mannosidosis and systemic lupus erythematosus. Eur. J. Pediatr. 163, 192\u2013195 (2004).","journal-title":"Eur. J. Pediatr."},{"key":"1352_CR183","volume":"30","author":"P Lipinski","year":"2022","unstructured":"Lipinski, P. et al. Long-term outcome of patients with alpha-mannosidosis \u2014 a single center study. Mol. Genet. Metab. Rep. 30, 100826 (2022).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"1352_CR184","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/humu.22787","volume":"36","author":"HM Riise Stensland","year":"2015","unstructured":"Riise Stensland, H. M. et al. amamutdb.no: a relational database for MAN2B1 allelic variants that compiles genotypes, clinical phenotypes, and biochemical and structural data of mutant MAN2B1 in \u03b1-mannosidosis. Hum. Mutat. 36, 581\u2013586 (2015).","journal-title":"Hum. Mutat."},{"key":"1352_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2024.101832","volume":"2","author":"JM Lander","year":"2024","unstructured":"Lander, J. M. et al. Velmanase alfa approved for treatment of non-central nervous system manifestations of alpha-mannosidosis: a therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. Open. 2, 101832 (2024).","journal-title":"Genet. Med. Open."},{"key":"1352_CR186","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/bmt.2011.99","volume":"47","author":"M Mynarek","year":"2012","unstructured":"Mynarek, M. et al. Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients. Bone Marrow Transpl. 47, 352\u2013359 (2012).","journal-title":"Bone Marrow Transpl."},{"key":"1352_CR187","unstructured":"Rossignol, F., Wang, H. & Ferreira, C. Prolidase deficiency. In GeneReviews (ed Adam, M. P. et al.) (2022)."},{"key":"1352_CR188","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/biology9050108","volume":"9","author":"M Spodenkiewicz","year":"2020","unstructured":"Spodenkiewicz, M. et al. Clinical genetics of prolidase deficiency: an updated review. Biology 9, 10 (2020).","journal-title":"Biology"},{"key":"1352_CR189","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jbspin.2018.10.007","volume":"86","author":"F Chasset","year":"2019","unstructured":"Chasset, F. et al. Rare diseases that mimic systemic lupus erythematosus (Lupus mimickers). Jt Bone Spine 86, 165\u2013171 (2019).","journal-title":"Jt Bone Spine"},{"key":"1352_CR190","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.723003","volume":"8","author":"I Eni-Aganga","year":"2021","unstructured":"Eni-Aganga, I., Lanaghan, Z. M., Balasubramaniam, M., Dash, C. & Pandhare, J. PROLIDASE: a review from discovery to its role in health and disease. Front. Mol. Biosci. 8, 723003 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"1352_CR191","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S0022-2275(20)40138-5","volume":"8","author":"PB Schneider","year":"1967","unstructured":"Schneider, P. B. & Kennedy, E. P. Sphingomyelinase in normal human spleens and in spleens from subjects with Niemann-Pick disease. J. Lipid Res. 8, 202\u2013209 (1967).","journal-title":"J. Lipid Res."},{"key":"1352_CR192","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","volume":"120","author":"EH Schuchman","year":"2017","unstructured":"Schuchman, E. H. & Desnick, R. J. Types A and B Niemann-Pick disease. Mol. Genet. Metab. 120, 27\u201333 (2017).","journal-title":"Mol. Genet. Metab."},{"key":"1352_CR193","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/labinvest.3780311","volume":"81","author":"R Dhami","year":"2001","unstructured":"Dhami, R., He, X., Gordon, R. E. & Schuchman, E. H. Analysis of the lung pathology and alveolar macrophage function in the acid sphingomyelinase-deficient mouse model of Niemann-Pick disease. Lab. Invest. 81, 987\u2013999 (2001).","journal-title":"Lab. Invest."},{"key":"1352_CR194","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13023-021-01842-0","volume":"16","author":"MM McGovern","year":"2021","unstructured":"McGovern, M. M. et al. Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation. Orphanet J. Rare Dis. 16, 212 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"1352_CR195","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1542\/peds.2007-3016","volume":"122","author":"MM McGovern","year":"2008","unstructured":"McGovern, M. M. et al. A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics 122, e341\u2013e349 (2008).","journal-title":"Pediatrics"},{"key":"1352_CR196","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jpeds.2006.06.034","volume":"149","author":"MP Wasserstein","year":"2006","unstructured":"Wasserstein, M. P. et al. Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann-Pick disease. J. Pediatr. 149, 554\u2013559 (2006).","journal-title":"J. Pediatr."},{"key":"1352_CR197","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13023-023-02686-6","volume":"18","author":"T Geberhiwot","year":"2023","unstructured":"Geberhiwot, T. et al. Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann\u2013Pick disease types A, B and A\/B). Orphanet J. Rare Dis. 18, 85 (2023).","journal-title":"Orphanet J. Rare Dis."},{"key":"1352_CR198","volume":"38","author":"A Doerr","year":"2024","unstructured":"Doerr, A. et al. Diagnostic odyssey for patients with acid sphingomyelinase deficiency (ASMD): exploring the potential indicators of diagnosis using quantitative and qualitative data. Mol. Genet. Metab. Rep. 38, 101052 (2024).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"1352_CR199","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41436-021-01156-3","volume":"23","author":"GA Diaz","year":"2021","unstructured":"Diaz, G. A. et al. One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency. Genet. Med. 23, 1543\u20131550 (2021).","journal-title":"Genet. Med."},{"key":"1352_CR200","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.gim.2022.03.021","volume":"24","author":"M Wasserstein","year":"2022","unstructured":"Wasserstein, M. et al. A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: one-year results. Genet. Med. 24, 1425\u20131436 (2022).","journal-title":"Genet. Med."},{"key":"1352_CR201","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s13023-023-02983-0","volume":"18","author":"MP Wasserstein","year":"2023","unstructured":"Wasserstein, M. P. et al. Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial. Orphanet J. Rare Dis. 18, 378\u00a0(2023).","journal-title":"Orphanet J. Rare Dis."},{"key":"1352_CR202","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s13023-022-02587-0","volume":"17","author":"GA Diaz","year":"2022","unstructured":"Diaz, G. A. et al. Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results. Orphanet J. Rare Dis. 17, 437\u00a0(2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"1352_CR203","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/rheumatology\/keaa165","volume":"60","author":"C Kosukcu","year":"2021","unstructured":"Kosukcu, C. et al. Whole exome sequencing in unclassified autoinflammatory diseases: more monogenic diseases in the pipeline? Rheumatology 60, 607\u2013616 (2021).","journal-title":"Rheumatology"},{"key":"1352_CR204","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3899\/jrheum.171358","volume":"45","author":"ED Batu","year":"2018","unstructured":"Batu, E. D. et al. Whole exome sequencing in early-onset systemic lupus erythematosus. J. Rheumatol. 45, 1671\u20131679 (2018).","journal-title":"J. Rheumatol."},{"key":"1352_CR205","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1002\/humu.24165","volume":"42","author":"BM Fathalla","year":"2021","unstructured":"Fathalla, B. M., Alsarhan, A., Afzal, S., El Naofal, M. & Abou Tayoun, A. The genomic landscape of pediatric rheumatology disorders in the Middle East. Hum. Mutat. 42, e1\u2013e14 (2021).","journal-title":"Hum. Mutat."},{"key":"1352_CR206","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12969-022-00722-6","volume":"20","author":"WF Lee","year":"2022","unstructured":"Lee, W. F. et al. Characteristics and genetic analysis of patients suspected with early-onset systemic lupus erythematosus. Pediatr. Rheumatol. Online J. 20, 68 (2022).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1352_CR207","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12969-019-0349-y","volume":"17","author":"I Tirosh","year":"2019","unstructured":"Tirosh, I. et al. Whole exome sequencing in childhood-onset lupus frequently detects single gene etiologies. Pediatr. Rheumatol. Online J. 17, 52 (2019).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1352_CR208","doi-asserted-by":"publisher","first-page":"214","DOI":"10.55563\/clinexprheumatol\/zte897","volume":"39","author":"G Li","year":"2021","unstructured":"Li, G. et al. Genetic heterogeneity in Chinese children with systemic lupus erythematosus. Clin. Exp. Rheumatol. 39, 214\u2013222 (2021).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1352_CR209","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00296-019-04252-5","volume":"39","author":"I Karacan","year":"2019","unstructured":"Karacan, I. et al. Diagnostic utility of a targeted next-generation sequencing gene panel in the clinical suspicion of systemic autoinflammatory diseases: a multi-center study. Rheumatol. Int. 39, 911\u2013919 (2019).","journal-title":"Rheumatol. Int."},{"key":"1352_CR210","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13023-020-01645-9","volume":"16","author":"A Mehta","year":"2021","unstructured":"Mehta, A. et al. A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide. Orphanet J. Rare Dis. 16, 8 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"1352_CR211","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.119883","volume":"562","author":"S Mansoor","year":"2024","unstructured":"Mansoor, S., Qamar, R. & Azam, M. Inborn errors of metabolism: historical perspectives to contemporary management. Clin. Chim. Acta 562, 119883 (2024).","journal-title":"Clin. Chim. Acta"},{"key":"1352_CR212","first-page":"97","volume":"51","author":"GC Hard","year":"1970","unstructured":"Hard, G. C. Some biochemical aspects of the immune macrophage. Br. J. Exp. Pathol. 51, 97\u2013105 (1970).","journal-title":"Br. J. Exp. Pathol."},{"key":"1352_CR213","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/bies.201300084","volume":"35","author":"EM Palsson-McDermott","year":"2013","unstructured":"Palsson-McDermott, E. M. & O\u2019Neill, L. A. The Warburg effect then and now: from cancer to inflammatory diseases. Bioessays 35, 965\u2013973 (2013).","journal-title":"Bioessays"},{"key":"1352_CR214","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/nature09973","volume":"472","author":"AP West","year":"2011","unstructured":"West, A. P. et al. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature 472, 476\u2013480 (2011).","journal-title":"Nature"},{"key":"1352_CR215","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nature11986","volume":"496","author":"GM Tannahill","year":"2013","unstructured":"Tannahill, G. M. et al. Succinate is an inflammatory signal that induces IL-1\u03b2 through HIF-1\u03b1. Nature 496, 238\u2013242 (2013).","journal-title":"Nature"},{"key":"1352_CR216","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s42255-019-0083-2","volume":"1","author":"GL Seim","year":"2019","unstructured":"Seim, G. L. et al. Two-stage metabolic remodelling in macrophages in response to lipopolysaccharide and interferon-\u03b3 stimulation. Nat. Metab. 1, 731\u2013742 (2019).","journal-title":"Nat. Metab."},{"key":"1352_CR217","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s11914-020-00626-y","volume":"18","author":"Z Jiang","year":"2020","unstructured":"Jiang, Z., Byers, S., Casal, M. L. & Smith, L. J. Failures of endochondral ossification in the mucopolysaccharidoses. Curr. Osteoporos. Rep. 18, 759\u2013773 (2020).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1352_CR218","doi-asserted-by":"publisher","first-page":"115042","DOI":"10.1016\/j.bone.2019.115042","volume":"128","author":"SH Peck","year":"2019","unstructured":"Peck, S. H. et al. Molecular profiling of failed endochondral ossification in mucopolysaccharidosis VII. Bone 128, 115042 (2019).","journal-title":"Bone"},{"key":"1352_CR219","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/labinvest.3780345","volume":"81","author":"CM Simonaro","year":"2001","unstructured":"Simonaro, C. M., Haskins, M. E. & Schuchman, E. H. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab. Invest. 81, 1319\u20131328 (2001).","journal-title":"Lab. Invest."},{"key":"1352_CR220","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2353\/ajpath.2008.070564","volume":"172","author":"CM Simonaro","year":"2008","unstructured":"Simonaro, C. M. et al. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am. J. Pathol. 172, 112\u2013122 (2008).","journal-title":"Am. J. Pathol."},{"key":"1352_CR221","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1073\/pnas.0912937107","volume":"107","author":"CM Simonaro","year":"2010","unstructured":"Simonaro, C. M. et al. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc. Natl Acad. Sci. 107, 222\u2013227 (2010).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1352_CR222","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ymgme.2016.01.012","volume":"117","author":"LE Polgreen","year":"2016","unstructured":"Polgreen, L. E. et al. Elevated TNF-\u03b1 is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI. Mol. Genet. Metab. 117, 427\u2013430 (2016).","journal-title":"Mol. Genet. Metab."},{"key":"1352_CR223","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022447","volume":"6","author":"E Eliyahu","year":"2011","unstructured":"Eliyahu, E. et al. Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI. PLoS ONE 6, e22447 (2011).","journal-title":"PLoS ONE"},{"key":"1352_CR224","first-page":"75","volume":"10","author":"LE Polgreen","year":"2017","unstructured":"Polgreen, L. E. et al. Pilot study of the safety and effect of adalimumab on pain, physical function, and musculoskeletal disease in mucopolysaccharidosis types I and II. Mol. Genet. Metab. Rep. 10, 75\u201380 (2017).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"1352_CR225","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1252704","volume":"10","author":"NV Buchinskaya","year":"2023","unstructured":"Buchinskaya, N. V. et al. Evaluation of etanercept (a tumor necrosis factor alpha inhibitor) as an effective treatment for joint disease in mucopolysaccharidosis type I. A case report with whole-body magnetic resonance imaging. Front. Med. 10, 1252704 (2023).","journal-title":"Front. Med."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01352-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T01:02:28Z","timestamp":1774573348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01352-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":225,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1352"],"URL":"https:\/\/doi.org\/10.1038\/s41584-026-01352-y","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"9 January 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}